NY-ESO Phase I Study for Prostate Cancer
-
- STATUS
- Recruiting
-
- participants needed
- 38
-
- sponsor
- Baylor College of Medicine
Summary
Prostate cancer is the most common type of cancer found in American men, other than skin cancer. The American Cancer Society estimates that there will be about 218,890 new cases of prostate cancer in the United States in 2007. About 27,050 men will die of this disease. Prostate cancer is the second leading cause of cancer death in men. Lung cancer is the first. While 1 man in 6 will get prostate cancer during his lifetime, only 1 man in 34 will die of this disease. The death rate for prostate cancer is going down, and the disease is being found earlier as well. There is a great need for new treatment options for prostate cancer that can be given safely. One alternative to widely used conventional cancer treatments is to utilize the ability of the patient's immune system to target and kill tumor cells. A vaccine is a compound designed to strengthen the immune system (the cells and substances that protect the body from infection and foreign matter) to fight an illness such as infections or cancer. This vaccine is called NY-ESO-1 protein. NY-ESO protein (an antigen, which is a compound that is recognized by the immune system) is found in many cancers. Proteins such as NY-ESO-1 and LAGE-1 and their fragments are the targets the immune system needs to recognize cancer cells. If the immune system can recognize these antigens (foreign substances) it may be able to kill the cells that carry them. NY-ESO-1 can be found at different stages of cancers, and is likely to be expressed (shown) at some point in the lifecycle of these types of cancer (that are eligible for this study). Therefore this study tries to boost (strengthen) the immune system toward NY-ESO-1 protein regardless of whether it is found in the tumor or not.
Description
Nine subjects will participate in this Phase I study that is designed to evaluate the safety and biology of class I and class II NY-ESO-1/LAGE-1 vaccine with an intent to offer a therapeutic advantage. The treatment cycle is 6 subcutaneous injections administered every other week for 12 weeks of NY-ESO-1/LAGE-1 vaccine (weeks 1, 3, 5, 7, 9, 11 (±3 days)). The vaccinations will be given in the upper arm region, in a volume of 1 milliliter. The dose will be 1000 mcg of peptide (1 mg). Patients will be evaluated for clinical/immunological responses at weeks 5 and 11. The vaccine schedule is similar to that of many prior peptide vaccine studies, in which the schedule was based on earlier animal studies but empirically derived in human studies (32-34, 36-39). The first patients will be enrolled to receive subcutaneous vaccination with either class I or II NY-ESO-1/ LAGE-1 peptide (1000 mcg). Thus, the trial will test the toxicity of the vaccine with 3 patients in each of 2 vaccine groups, one receiving Class I (group I) and the other Class II peptide (group II). If no significant toxicity is observed after a treatment cycle of 12 weeks, then three patients will receive a combination of both peptides (group III).
Details
| Condition | Prostatic Neoplasms |
|---|---|
| Treatment | NY-ESO-1 class I and class II peptide vaccine, LAGE-1 class I and class II peptide vaccine |
| Clinical Study Identifier | NCT00711334 |
| Sponsor | Baylor College of Medicine |
| Last Modified on | 7 November 2020 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer